Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong confidence aTyr’s lead program efzofitimod will be ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a price target of $180.00. The company’s shares closed ...

BERLIN, February 17, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for the ...

HERZLIYA, Israel and CALGARY, AB, Feb. 18, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in ...

Our vision for our lead asset NOX-A12 remains clear: to secure approval for its use in glioblastoma patients through a strategic partnership with a pharmaceutical company, supported by ...

Innovative Chronic Pain Treatment Receives IP Protection in India's $55 Billion Pharmaceutical Market HERZLIYA, Israel and CALGARY, AB, Feb. 18, 2025 /PRNewswire/ -- Innocan Pharma Corporation ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

In 2025, pharma companies must enable an instantaneous data-to-decision value chain that is AI-powered, cloud-based, and product-enabled. You need to ingest data rapidly, manage it, keep it ...

A nurse prepares to administer a malaria vaccine to an infant at the health center in Datcheka, Cameroon January 22, 2024. REUTERS/Desire Danga Essigue/File Photo The U.S. government's foreign aid ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...